Navigation Links
Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
Date:4/27/2013

NANJING, China, April 27, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, announced today that the Company filed its annual report on Form 20-F for the year ended December 31, 2012 with the Securities and Exchange Commission on April 26, 2013, U.S. Eastern Time. The annual report can be accessed on the Company's investor relations website at http://ir.simcere.com. The Company will provide a hard copy of the annual report containing its audited financial statements for the year ended December 31, 2012, free of charge, to its shareholders and ADS holders upon request.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ("Simcere") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:

Email: ir@simcere.com

In Nanjing:

Jie Liu D'Elia

Vice President

Simcere Pharmaceutical Group

Tel: 86-25-8556-6666*8857


'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
2. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
3. Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere Vaxtec
4. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Legal Counsel
5. Simcere Pharmaceutical Group Announces Receipt of "Going Private" Proposal
6. Simcere Pharmaceutical Group Reports Preliminary Unaudited Fourth Quarter And Full Year 2012 Results
7. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Thursday, March 7, 2013
8. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
9. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
10. Simcere Pharmaceutical Group to Announce Third Quarter 2012 Financial Results on Thursday, November 15, 2012
11. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014  Sanguine Biosciences – a biotechnology company ... recruitment – will use its proprietary mobile application ... Inc. find and recruit people diagnosed with Congenital ... to participate in voluntary research, which will be ... hopefully aid in informing the development of potential ...
(Date:11/18/2014)... and SAN DIEGO , ... HPPI), a clinical stage biopharmaceutical company that discovers, ... patients with cancer, announced today that it filed ... U.S. Food and Drug Administration (FDA) on Friday, ... covers HPPI,s proposed clinical development of a patented ...
(Date:11/18/2014)... 18, 2014  TransCelerate BioPharma Inc. ("TransCelerate") ... manuscript on Risk-Based Monitoring (RBM), " Evaluating ... Measure in Clinical Trials ," in the ... Regulatory Science  (TIRS) journal. Developed by TransCelerate,s ... the manuscript examines the value of Source ...
Breaking Medicine Technology:Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research 2HedgePath Pharmaceuticals Files IND Application 2HedgePath Pharmaceuticals Files IND Application 3HedgePath Pharmaceuticals Files IND Application 4TransCelerate BioPharma Inc. Publishes Recommendation on Use of Source Data Verification in Risk-Based Monitoring, Releases Third Update on Initiative Progress 2TransCelerate BioPharma Inc. Publishes Recommendation on Use of Source Data Verification in Risk-Based Monitoring, Releases Third Update on Initiative Progress 3
... , , ... company leading the scientific research of neurogenesis using its proprietary ... central nervous system (CNS) diseases, announced today results from the ... dose buspirone and melatonin, for the treatment of major depressive ...
... , , HOUSTON, July ... the U.S. Food and Drug Administration ("FDA") has approved the company,s proposal ... patients treated with VNS Therapy(TM). , , ... of study subjects from 460 to 330 and completed enrollment of 331 ...
Cached Medicine Technology:Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression 2Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression 3Cyberonics Provides Update on Depression Post-Approval Study 2Cyberonics Provides Update on Depression Post-Approval Study 3
(Date:11/18/2014)... (PRWEB) November 18, 2014 Hawthorne cosmetic ... affordable for patients. Nearly 70 percent of Americans over the ... the age of 74, 25 percent are missing not just ... options are available, but only one offers a look, feel, ... , This special includes a complimentary consultation that allows patients ...
(Date:11/18/2014)... -- Routine screening for heart disease isn,t effective for ... at high risk for a heart attack, according to ... not help prevent heart attacks or help patients avoid ... pain that occurs when the heart doesn,t receive enough ... best way to manage risks for heart-related complications, the ...
(Date:11/18/2014)... November 18, 2014 Global ... using the telehealth platform to bring quality healthcare ... this passion, GPT created Global Partnership for TeleHealth ... already existing telehealth network. GPTM focuses specifically ... overseas, and disaster relief organizations. , ...
(Date:11/18/2014)... Sorrel Sky Gallery welcomes jewelry artist ... of her beautiful, one-of-a-kind pieces. Just in time for the ... gallery, Friday, December 5 from 5 – 7:30 p.m. for ... artistic creations began at her grandmother’s kitchen table at a ... designs. She studied at the Gemological Institute of America in ...
(Date:11/18/2014)... By Dennis Thompson ... (HealthDay News) -- Daily low-dose aspirin therapy may not ... suggests. The study, which involved more than ... major difference in heart-related deaths or non-fatal heart attacks ... who didn,t. "It indicates that primary prevention ...
Breaking Medicine News(10 mins):Health News:Hawthorne Dentist, Dr. Yashari, is Now Making Dental Implants More Affordable for Patients 2Health News:Study Finds No Added Benefit From Routine Heart Scans for Diabetics 2Health News:Study Finds No Added Benefit From Routine Heart Scans for Diabetics 3Health News:Global Partnership for TeleHealth (GPT) is Focused on Using the telehealth Platform to Bring Quality Healthcare to Populations in Need Worldwide 2Health News:Elizabeth Showers Trunk Show & Personal Appearance Hosted by Sorrel Sky Gallery 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 3
... to combat HIV/AIDS, President A P J Abdul Kalam today ... the deadly disease is still out of reach of the ... companies have done formidable job in bringing down the price ... this reduction does not make the drug affordable to the ...
... In a plush Bangkok ballroom one evening in May, ... on foie gras, oysters and sushi while they talked ... of Alaskan king crab, French wine and melt-in-your-mouth Parma ... ways of putting Bangkok on the international culinary map. ...
... of Australia's biggest bread companies is not happy with the ... acid. They are petitioning the state and federal// governments to ... proposal is to enhance the foliate levels in women of ... defects, such as spina bifida. ,If you ask ...
... Chulanont, has defended his government's move to allow the introduction ... worries over intellectual property rights in the kingdom. ... explain our action to other countries as well the world ... Health Minister Mongkol Na Songkhla will be traveling to the ...
... skin’s ability to replace the tissue it sloughs off is ... Harvard Medical School published// in the May 4 issue of ... not only for skin, but for many epithelial tissues including ... stem cells turns out to be the p63 gene, a ...
... in the journal Proceedings of the National Academy of ... antibiotic which inhibits the work of an enzyme that ... ,Although such so-called gene-for-gene interactions are thought ... a single gene in a pathogen targeting a single ...
Cached Medicine News:Health News:Bangkok Lures Visitors With Its Growing Gourmet Scene 2Health News:Thailand Unfazed As US Worries Over Copyright Violations 2Health News:Master Regulatory Gene of Epithelial Stem Cells Identified 2Health News:Scientists Discover Rare ‘gene-for-gene’ Interaction That Helps Bacteria Kill Their Ho 2
An Innovative New System to Help You Meet the Challenges of Anterior Spine Surgery...
... QuickSite model 1056K LV lead is ... to promote shorter procedure times, delivering ... and reliability., ,The QuickSite LV lead ... left ventricular lead, including such features ...
... a new generation locking nail system, bringing ... separate nailing systems to create a single, ... bone fractures. , ,Through the development ... approach, both in principle and in detail, ...
... Intramedullary fixation has greatly ... tibial fractures. The Biomet Low ... indicated in the treatment of ... metastatic disease with pathologic or ...
Medicine Products: